Founding Story

Admittance Technologies is the brainchild of Marc D. Feldman, M.D. It is an early stage, Austin, TX based company committed to delivering electrical engineering solutions to heart failure patients. Admittance’s IP portfolio and engineering prototypes are the evolution of a collaborative research program at The University of Texas on both the San Antonio and Austin campuses for the last 14 years. The research produced by these groups has been published in multiple journals, resulted in 9 patents either issued or pending dating as far back as 1998, and sales of over 150 animal systems to date via our industry partner, Transonic Scisense Inc., in Canada.

Marc D. Feldman, MD | Founder

Dr-FeldmanDr. Feldman is a practicing cardiologist and research professor at UTHSCSA, and a Professor in Biomedical Engineering at UT Austin and UTSA. He is an internationally recognized cardiologist and frequent recipient of the “Best Doctors in America®” award.

The first company Dr. Feldman founded, Setagon, Inc., was acquired by Medtronic in 2007. CardoSpectra is the second company founded by Dr. Feldman. CardioSpectra was acquired in 2007 by Volcano Corporation (San Diego, CA). CardioSpectra achieved its first milestone with CE Mark in 2010 and Volcano is currently applying for FDA approval for patient sales in the US. Feldman was awarded the UT System Chancellor’s Award for Entrepreneurship and Innovation for this success. CardioSpectra was the first and remains to this day one of the most successful start-ups funded by the Texas ETF.

 

Wes Johnson | Chief Executive Officer and Director

Wes_2Mr. Johnson has held various senior management positions in the medical device industry for 30 years. He has raised over $210 million in private and public equity and been involved with the successful sale of three start-up medical device companies. Prior to becoming CEO of Admittance Technologies in February 2013, Mr. Johnson was CEO of CardioKinetix, Inc. and prior to that was General Manager of Abbott Spine, S.A., a division of Abbott Laboratories. Mr. Johnson also served as Chief Financial Officer and VP, Operations at Spinal Concepts, Inc. and as CFO of Urologix, Inc. and Orthofix, Inc.

Mr. Johnson serves on the board of directors for AngioDynamics, Inc. and Minimus Spine, Inc. He holds a BBA in accounting from Texas A&M University and became a certified public accountant in 1981.

 

John Porterfield, PhD | Chief Scientific Officer

John PorterfieldDr. Porterfield is working toward the goal of commercializing his research for use in humans.

In 2008, Dr. Porterfield successfully validated the admittance technique by performing experiments that showed for the first time that using a complex measurement allowed the separation of blood and muscle. This directly led to improvements in the accuracy of catheter-based blood volume measurements in mice and larger animals.

Dr. Porterfield received his BS in Engineering from Oklahoma State University and his MSE and PhD from The University of Texas at Austin.

 

Anil Kottam, PhD | Principal Scientist

Dr. Anil Kottam joined Admittance Technologies in 2013, after several years of experience designing systems for pre-clinical research in the biomedical industry. He has co-authored multiple papers on the measurement of electrical properties of tissue and has designed and developed instrumentation and algorithms for in vivo LV volume measurements. Dr. Kottam has many years of experience in using conductance catheter technology to determine volumes in both large and small animals and has a profound understanding of the benefits and flaws of the technique. He is actively involved in implementing more accurate algorithms, experimental techniques and instrumentation to improve the accuracy of ventricular volume estimation and tissue electrical properties.

Dr. Kottam received his MSE and PhD in biomedical engineering from the University of Texas at Austin.